Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Good afternoon, everyone. Very quickly for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. [Now with] that out of the way, welcome. Joined by Josh Brumm, President, CEO; Oxana Beskrovnaya -- did I get close to that? -- CSO; and Wildon Farwell, CMO of Dyne. First time having Dyne at the Morgan Stanley Healthcare Conference, and we're excited to have them here.
Let me very quickly set the stage. Dyne is a clinical stage muscle disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases. Company is applying its proprietary FORCE platform and now has two clinical stage programs in myotonic dystrophy Type 1 or DM1, as well as Duchenne muscular dystrophy or DMD. So, we're happy to have Dyne here. I think we'll jump right in. You had a really busy morning.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
